How PDS0101 patent coverage reshapes competitive risk in HPV16 positive head and neck cancer development
PDS Biotechnology strengthens PDS0101 patent protection as Phase 3 strategy evolves. Discover what this changes for immunotherapy competition.
Pharma & Biotech
Pharma & Biotech
Saudi FDA approves ImmunityBio’s ANKTIVA in NSCLC: What this means for immunotherapy 2.0
Find out how ImmunityBio’s subcutaneous immunotherapy ANKTIVA secured Saudi approval for NSCLC and what it means for global immuno-oncology.
Pharma & Biotech
Why Biocytogen and Acepodia are betting on BsAD2Cs for next-gen cancer therapy
Biocytogen and Acepodia expand their ADC collaboration to evaluate dual-payload bispecifics. Find out how this model could reshape solid tumor therapy.
Pharma & Biotech
Can Biohaven’s BHV-1510 avoid the safety pitfalls of existing Trop2 ADCs in solid tumors?
Biohaven Ltd. presented updated Phase 1 clinical data on BHV-1510, its next-generation Trop2-targeting antibody-drug conjugate, at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London. The results, derived from a heavily pretreated population with advanced or metastatic solid tumors, showed encouraging response rates across non-small cell lung cancer, endometrial cancer, and urothelial